Gilead, Arcus: Encouraging Data in First-Line Treatment for Upper GI Cancers

 Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression –

– Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers –

– Detailed results will be presented on November 7 at 12pm PT / 3pm ET during the ASCO Monthly Plenary Series –

https://www.businesswire.com/news/home/20231106343567/en/